Under the Medicare drug negotiations provisions in the reconciliation bill, the federal government would see its outlays reduced by about $300 billion. That reduction wouldn’t result from cuts in benefits. Instead, Medicare would be empowered to leverage its market power to pay lower prices for certain drugs.
The Inflation Reduction Act includes several landmark health care provisions that would lower prescription drug costs for people with Medicare, reduce Medicare drug spending and extend enhanced subsidies for Affordable Care Act marketplace coverage. On…
It’s hard to concisely put into words how frustrated physicians are right now. How many other professional groups out there have to fight to not have their compensation cut multiple times a year? Recently, CMS released its proposed physician fee …
Private equity firms are seeing opportunities for profit in hospice care, once the domain of nonprofit organizations. The investment companies are transforming the industry — and might be jeopardizing patient care — in the process.
The brief provides a quick explainer of the prescription drug provisions in legislative text released by the Senate Finance Committee to be included in a forthcoming reconciliation bill and presents new estimates on how many Medicare beneficiaries coul…
This slideshow explains the prescription drug provisions proposed in the Senate Reconciliation Proposal.
The advocacy group American Commitment said empowering Medicare to negotiate drug prices would raid it of billions of dollars. Drug pricing experts say that that’s not the case and that such policies would instead reduce costs for the Medicare program and seniors.
Two things happened in Washington this week that were inevitable: President Joe Biden tested positive for covid-19, and the Senate agreed to move forward on a budget bill that includes only a sliver of what Biden hoped it would. Still, the bill to allow Medicare to negotiate some drug prices, cap out-of-pocket drug costs for seniors, and extend temporary subsidies for Affordable Care Act insurance premiums would represent a major step if Democrats can get it across the finish line. Meanwhile, abortion battles continue to escalate around the country, with Texas leading the way in restrictions. Shefali Luthra of The 19th, Joanne Kenen of the Johns Hopkins Bloomberg School of Public Health and Politico, and Rachel Cohrs of Stat join KHN’s Julie Rovner to discuss these issues and more. Also this week, Rovner interviews Dr. Jack Resneck Jr., the new president of the American Medical Association.
A rapidly changing landscape for abortion has left patients, providers, employers, and lawmakers alike wondering what is and is not legal and what to do next. Meanwhile, Democrats in Congress have resumed negotiations on legislation to lower drug prices and, potentially, continue expanded insurance subsidies for the Affordable Care Act. Alice Miranda Ollstein of Politico, Tami Luhby of CNN, and Sandhya Raman of CQ Roll Call join KHN’s Julie Rovner to discuss these issues and more. Plus, for extra credit, the panelists recommend their favorite health policy stories of the week they think you should read, too.
A new federal rescue program that pays rural hospitals to shutter underused inpatient units and focus solely on emergency rooms and outpatient care hasn’t generated much interest yet.
